CALGB 100801 (Alliance): A phase II multi-center study of the addition of azacitidine (AZA) following allogeneic transplantation using a targeted busulfan based conditioning regimen for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML)
         Google Scholar   
Citation:
Bone Marrow Transplantation vol 50 (S1) abstr P640
Meeting Instance:
EBMT 2015
Year:
2015
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3067  
Program:
OGC
Primary Committee:
Transplant
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                       
Networks:
 
Study
CALGB-100801
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: